Source:http://linkedlifedata.com/resource/pubmed/id/17012841
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
2007-1-9
|
pubmed:abstractText |
p63 and p73, the p53 family proteins, are similar to p53 in many aspects: structural homology, transactivation of p53-downstream genes, and induction of apoptosis. Interestingly, they also differ from p53; in particular, they are not inhibited by viral oncoproteins such as HPV E6. This feature would be an advantage over p53 in HPV-associated cancers and therefore, we evaluated the therapeutic potentials of various p53 family proteins (p73alpha, p73beta, p63alpha and p63gamma) against HPV-infected cervical cancers. In clonogenic assay, exogenous expression of p73alpha, p73beta and p63gamma inhibited the colony formation of HPV-positive cervical cancer cells under G418- selection while p53 could not. Recombinant adenoviruses Ad/CMVp73alpha, Ad/CMVp73beta and Ad/CMVp63gamma induced potent apoptosis in all infected cervical cancers (CasKi, SiHa, HeLa, C33A, SNU682, SNU17, SNU1005, SNU703), irrespective of their HPV-infection status. Unfortunately however, Ad/CMVp73alpha, Ad/CMVp73beta, and Ad/CMVp63gamma inhibited also normal cells such as endothelial cells, fibroblasts, and keratinocytes thus, tumorspecific promoter was indispensable to the p53 family proteins-based therapy. Here we report a stringent tumor killing by p73beta in combination with ESM6, a synthetic promoter targeting the DNA tumor virusassociated cancers. Recombinant adenoviruses encoding p73beta by ESM6 (Ad/ESM6p73beta and Ad/ESM6p73bENH) expressed p73beta and induced apoptosis only in the cancer cells but not in normal cells. Collectively, we suggest that the p53 family proteins are potent therapeutic agents for HPV-associated uterine cervical cancers and ESM6 mediated expression of the p53 family proteins would be a safe and strong tumor targeting strategy.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1538-4047
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
5
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1502-10
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:17012841-Adenoviridae,
pubmed-meshheading:17012841-Cell Line,
pubmed-meshheading:17012841-Cell Line, Tumor,
pubmed-meshheading:17012841-Cloning, Molecular,
pubmed-meshheading:17012841-DNA Primers,
pubmed-meshheading:17012841-E2F1 Transcription Factor,
pubmed-meshheading:17012841-Female,
pubmed-meshheading:17012841-Gene Therapy,
pubmed-meshheading:17012841-Genes, p53,
pubmed-meshheading:17012841-Humans,
pubmed-meshheading:17012841-Promoter Regions, Genetic,
pubmed-meshheading:17012841-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:17012841-Uterine Cervical Neoplasms
|
pubmed:year |
2006
|
pubmed:articleTitle |
Enhanced specificity of the p53 family proteins-based adenoviral gene therapy in uterine cervical cancer cells with E2F1-responsive promoters.
|
pubmed:affiliation |
Cancer Research Institute, Seoul National University Hospital, Seoul, Korea.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|